Serina Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $41.7M
- Price
- $2.87
- % Change (Daily % change from the live per-ticker quote feed.)
- +8.30%
- Volume
- 46.1K
About
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Quick stats
Shares outstanding15.0M
Computed float6.9M
Float / shares45.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001708599
Websitehttp://www.serinatx.com
AI Summary
AI-generated1/20
minorneutralearnings
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Serina Therapeutics reported Q2 2026 financial results, highlighting a net loss of $8.9 million ($0.55 per share) on zero revenue, while cash reserves rose to $23.0 million following recent financing activities.
Operationally, the company completed enrollment and dosing in Cohort 1 of the Phase 1b registrational study for SER-252 ahead of schedule, with top-line data from the single-ascending-dose arm targeted for the first half of 2027.
Serina also announced a development partnership with Gannet BioChem for manufacturing support and appointed Farrell Simon, Pharm.D., to its Board of Directors, strengthening its commercial and technical capabilities.
Red flags
- Zero revenue for Q2 2026 vs $130k in Q2 2025
- Net loss widened to $8.9M from $6.6M YoY
- R&D and G&A expenses increased significantly YoY
- Reliance on PIPE financing for cash balance